About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Rnf186tm1Ktak
targeted mutation 1, Kiyoshi Takeda
MGI:6343556
Summary 1 genotype
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Rnf186tm1Ktak/Rnf186tm1Ktak involves: 129S4/SvJae * C57BL/6 MGI:6362820


Genotype
MGI:6362820
hm1
Allelic
Composition
Rnf186tm1Ktak/Rnf186tm1Ktak
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rnf186tm1Ktak mutation (0 available); any Rnf186 mutation (11 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
N
• mice raised under SPF conditions grow healthy and show normal large intestine and ileum histology with no apparent changes in ER morphology of colonic epithelia at 8 weeks of age or any significant inflammatory changes in the large intestine at 1 year of age
• whole-cell lysates of colonic epithelial cells from 8-week-old mice show increased protein expression of occludin (a component of tight junction molecules); moreover, occludin is broadly expressed in the cytoplasm, rather than the apical side, of colonic epithelia, indicating altered occludin distribution
• protein expression of SRPRB, GRP78 and GNB2 is increased in colonic epithelial cells, indicating altered expression patterns of RNF186 substrates
• at 8 weeks and 1 year of age, the permeability of small organic solutes, such as dextran and Lucifer yellow, is significantly increased in the large intestine relative to wild-type controls
• however, the permeability of inorganic ions in the large intestine is normal
• DSS-treated mice show significantly higher numbers of TUNEL- and active caspase-3-positive cells in colonic epithelial cells than DSS-treated wild-type controls at 4 days after treatment
• tunicamycin-treated mice show significantly higher numbers of TUNEL-positive cells in colonic epithelial cells than tunicamycin-treated wild-type controls at 48 h after treatment
• following oral administration of dextran sulfate sodium (DSS), mice show more severe weight loss and a reduced survival rate, with a significantly higher colitis score than DSS-treated wild-type controls at 4 and 8 days after treatment, as well as enhanced protein expression of SRPRB, GRP78, and GNB2 in colonic epithelial cells at 4 days after treatment
• oxazolone-treated mice show a more severe weight loss at 1 and 2 days after treatment, with a significantly higher colitis score than oxazolone-treated wild-type controls at 4 after treatment
• following oral administration of DSS, mice show a significantly lower survival rate than DSS-treated wild-type controls at 8 to 12 days after treatment

cellular
• DSS-treated mice show significantly higher numbers of TUNEL- and active caspase-3-positive cells in colonic epithelial cells than DSS-treated wild-type controls at 4 days after treatment
• tunicamycin-treated mice show significantly higher numbers of TUNEL-positive cells in colonic epithelial cells than tunicamycin-treated wild-type controls at 48 h after treatment
• DSS-treated mice exhibit enhanced ER stress in colonic epithelial cells, as shown by markedly increased expression of CHOP and spliced XBP1 (sXBP1) at 4 days after treatment

mortality/aging
• following oral administration of DSS, mice show a significantly lower survival rate than DSS-treated wild-type controls at 8 to 12 days after treatment
• following i.p. injection of tunicamycin (an ER stress inducer), 13 of 18 mice succumb within 96 h of challenge relative to only 1 of 13 tunicamycin-treated wild-type controls

immune system
• following oral administration of dextran sulfate sodium (DSS), mice show more severe weight loss and a reduced survival rate, with a significantly higher colitis score than DSS-treated wild-type controls at 4 and 8 days after treatment, as well as enhanced protein expression of SRPRB, GRP78, and GNB2 in colonic epithelial cells at 4 days after treatment
• oxazolone-treated mice show a more severe weight loss at 1 and 2 days after treatment, with a significantly higher colitis score than oxazolone-treated wild-type controls at 4 after treatment
• following oral administration of DSS, mice show a significantly lower survival rate than DSS-treated wild-type controls at 8 to 12 days after treatment

homeostasis/metabolism
• following i.p. injection of tunicamycin (an ER stress inducer), 13 of 18 mice succumb within 96 h of challenge relative to only 1 of 13 tunicamycin-treated wild-type controls





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
10/29/2024
MGI 6.24
The Jackson Laboratory